Abstract
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
Current Respiratory Medicine Reviews
Title:An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
Volume: 13 Issue: 1
Author(s): Amelia Licari , Riccardo Castagnoli, Elisa Panfili, Alessia Marseglia, Ilaria Brambilla and Gian Luigi Marseglia*
Affiliation:
- Department of Pediatrics, University of Pavia, Pavia,Italy
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
Abstract: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
Export Options
About this article
Cite this article as:
Licari Amelia , Castagnoli Riccardo , Panfili Elisa , Marseglia Alessia , Brambilla Ilaria and Luigi Marseglia Gian *, An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases, Current Respiratory Medicine Reviews 2017; 13 (1) . https://dx.doi.org/10.2174/1573398X13666170616110738
DOI https://dx.doi.org/10.2174/1573398X13666170616110738 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Mechanisms and Therapeutic Implications of Asthma Circadian Rhythm
Current Respiratory Medicine Reviews B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Electronic Monitoring of Adherence to Inhaled Medication in Asthma
Current Respiratory Medicine Reviews New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Structure-Function Relationships of Plasminogen Activator Inhibitor-1 and Its Potential as a Therapeutic Agent
Current Drug Targets Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Role of FoxP3<sup>+</sup> Treg Cells Mediating Immune Suppression in Leprosy
Current Immunology Reviews (Discontinued) Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Induction of Oral Tolerance with Transgenic Plants Expressing Antigens for Prevention/Treatment of Autoimmune, Allergic and Inflammatory Diseases
Current Pharmaceutical Biotechnology Leukotrienes and Atherosclerosis
Current Drug Targets Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Perception or Reality of Body Weight: Which Matters the Most to Adolescents’ Emotional Well-being?
Current Psychiatry Reviews RNA Interference (RNAi) Patents and Human Health Related Applications of RNAi
Recent Patents on DNA & Gene Sequences Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science